The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...